Category: 25850-22-0

Synthetic Route of 25850-22-0, An article , which mentions 25850-22-0, molecular formula is C7H15NO. The compound – 2,2-Dimethyltetrahydro-2H-pyran-4-amine played an important role in people’s production and life.

PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinaldamage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 25850-22-0, help many people in the next few years., Synthetic Route of 25850-22-0

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

25850-22-0, 25850-22-0, Name is 2,2-Dimethyltetrahydro-2H-pyran-4-amine, molecular formula is C7H15NO, belongs to Tetrahydropyrans compound, is a common compound. In a patnet, assignee is CANAN, Stacie S., once mentioned the new application about 25850-22-0

ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS

Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

25850-22-0, Each elementary reaction can be described in terms of its molecularity, the number of molecules that collide in that step. The slowest step in a reaction mechanism is the rate-determining step.you can also check out more blogs about 25850-22-0

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

25850-22-0, 2,2-Dimethyltetrahydro-2H-pyran-4-amine is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The 4-chloro-3-nitroquinoline-6-carbonitrile (4.74 g, 17.55 mmol) was suspended in MeCN (50 mL) then 2,2-dimethyltetrahydro-2H-pyran-4-amine (2.49 g, 19.3 mmol) was added, after the DIEA (4.54 g, 35.1 mmol) was added the mixture was stirred at 20C for 2h, turning brown to tan. LCMS indicated complete conversion to the desired product. The mixture was concentrated under vacuum, the residue was purified by silica gel column chromatography (PE/EtOAc = 1/1) to give the desired product (4.88 g, 85% yield) as yellow solid. The purity and structure of the product were confirmed by LCMS and 1HNMR. LCMS: RT 0.73 mm, MS 327.0) 1H NMR (400 MHz, DMSO-d6) O 9.09 (5,1H), 9.02 (5, 1H), 8.42 (d, J= 8.4 Hz, 1H), 8.15(dd, J= 8.6, 1.6 Hz, 1H), 8.01 (d, J= 8.6Hz, 1H), 3.98 (m, 1H), 3.76-3.66 (m, 1H), 3.60 (td, J = 12.2, 2.3 Hz, 1H), 2.01 (ddd, J =12.6, 4.6, 2.6 Hz, 1H), 1.93-1.82 (m, 1H), 1.67 (m, 1H), 1.56 (t, J = 12.3 Hz, 1H), 1.19(d, J = 7.7 Hz, 6H)., 25850-22-0

25850-22-0 2,2-Dimethyltetrahydro-2H-pyran-4-amine 3809203, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; PFIZER INC.; CHAPPIE, Thomas Allen; GALATSIS, Paul; GARNSEY, Michelle Renee; HELAL, Christopher John; HENDERSON, Jaclyn Louise; KORMOS, Bethany Lyn; KURUMBAIL, Ravi G.; MARTINEZ-ALSINA, Luis Angel; PETTERSSON, Martin Youngjin; STEPAN, Antonia Friederike; WAGER, Travis T.; (149 pag.)WO2018/163030; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

25850-22-0, 2,2-Dimethyltetrahydro-2H-pyran-4-amine is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 5-({[(3,4-dimethoxyphenyl)amino]carbonyl}amino)-2-{phenyl[4-(trifluoromethyl)phenyl]methoxy}benzoic acid (300 mg, 0.530 mmol), 1-hydroxy-1H-benzotriazole (122 mg, 0.798 mmol), 2,2-dimethyltetrahydro-2H-pyran-4-yl amine (137 mg, 1.06 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (126 mg, 0.660 mmol) and DMF (3 ML) was stirred under ice-cooling for 1 hour and at room temperature for 12 hours, was poured into water, and was extracted with ethyl acetate.. The extracted solution was washed with water, was dried with anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.. The residue was purified by silicagel column chromatography (hexane:ethyl acetate = 1:2), to obtain the titled compound as a solid.. This was recrystallized from hexane and ethyl acetate. 315 mg (87.7%) 1H-NMR (CDCl3) delta; 0.66 to 1.07 (8H, m), 1.27 to 1.86 (2H, m), 3.32 to 3.60 (2H, m), 3.84 (6H, s), 4.02 to 4.19 (1H, m), 6.32 (1H, s), 6.66 to 7.98 (18H, m), 25850-22-0

25850-22-0 2,2-Dimethyltetrahydro-2H-pyran-4-amine 3809203, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Chemical Industries, Ltd.; EP1437344; (2004); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25850-22-0,2,2-Dimethyltetrahydro-2H-pyran-4-amine,as a common compound, the synthetic route is as follows.

Production Example 321 (0641) 5-Benzyloxymethylisoxazole-3-carboxylic acid (0.24 g, 1.0 mmol), 4-amino-2,2-dimethyltetrahydropyran (0.18 ml, 1.2 mmol) and 1-hydroxybenzotriazole (0.01 g, 0.1 mmol) were added to chloroform (amylene addition product) (2.5 mL). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.24 g, 1.2 mmol) was added to the mixture at room temperature, and the mixture was stirred overnight. Then, dilute hydrochloric acid was added thereto, and the mixture was extracted twice with chloroform. The organic layer was passed through a short column to remove impurities, and then concentrated under reduced pressure. The residue was applied to a silica gel column chromatography to obtain 0.29 g of N-(2,2-dimethyltetrahydropyran-4-yl)-5-benzyloxymethylisoxa zole-3-carboxamidc: (hereinafter, referred to as Compound of Present Invention (335)) represented by the following formula. 1H-NMR(CDCl3, TMS, delta(ppm)):1.26(3H, s), 1.29(3H, s), 1.33-1.40(1H, m), 1.41-1.52(1H, m), 1.89-2.00(2H, m), 3.72-3.84(2H, m), 4.27-4.38(1H, m), 4.61(2H, s), 4.65(2H, s), 6.62(1H, br s), 6.72(1H, s), 7.30-7.40(5H, m)

25850-22-0, As the paragraph descriping shows that 25850-22-0 is playing an increasingly important role.

Reference£º
Patent; Sumitomo Chemical Company, Limited; MITSUDERA, Hiromasa; AWASAGUCHI, Kenichiro; AWANO, Tomotsugu; UJIHARA, Kazuya; EP2952096; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics